Phase 2 Window of Opportunity Study of IPI-549 in Patients 
with Locally Advanced HPV+ and HPV- Head and Neck 
Squamous Cell Carcinoma 
 
[STUDY_ID_REMOVED] 
 
Document Date: 12/3/2021 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 6.0 
Protocol  Date: December 03, 2021  
  Page  1 of 45 Phase  2 Window of Opportunity  Study  of IPI-549 in Patients  with  Locally  Advanced  HPV+  
and HPV - Head and Neck Squamous Cell Carcinoma  
PROTOCOL  
Study  Chair  (Principal  Investigator) 
Ezra Cohen, M.D. 
Professor of Medicine  
UC San Diego  Moores Cancer  Center  
3855 Health Sciences Drive 
La Jolla,  CA 92093-0658 
Phone: 858-534-6161 
Fax: 858-822-5754 
Email: ecohen@ucsd.edu  
Study  Site 
UCSD Moores Cancer Center  
3855 Health Sciences Drive #0698 
La Jolla, CA 92093-0698 
Protocol  Number  172058 
IND Number:  141417 
IND Holder  Name:  Ezra Cohen, MD  

UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 6.0 
Protocol  Date: December 03, 2021  
  Page  2 of 45  
  
LIST  OF INVESTIGATORS  
 
 
PRINCIPAL  INVESTIGATOR  
Ezra Cohen, M.D. 
Professor of Medicine  
UC San Diego  Moores Cancer  Center  
3855 Health Sciences Drive La Jolla,  CA 92093-0658 
Phone: 858-534-6161 Fax: 858-822-5754 
Email: ecohen@ucsd.edu  
 
CO-INVESTIGATORS  
Judith Varner, Ph.D. Professor of Medicine  
UC San Diego  Moores Cancer  Center  
3855 Health Sciences Drive La Jolla,  CA 92093-0820 
Phone: 858-822-0086 Fax: 858-822-1325 
Email: jvarner@ucsd.edu  
 
BIOSTATISTICIAN  
Karen  Messer,  Ph.D. 
Professor of Family Medicine & Public Health  
UC San Diego  Moores Cancer  Center  
3855 Health Sciences Drive #0901 La Jolla  CA, 92093-0901 
Phone: 858-822-6823 E-mail: kmesser@ucsd.edu
 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 6.0 
Protocol  Date: December 03, 2021  
  Page  3 of 45  
  
Signature  Page  
 
 
The signature below constitutes the approval of this protocol and the attachments, and provides  
the necessary assurances that this trial will be conducted according to all stipulations of the  
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements  and applicable U.S. federal regulations  and ICH guidelines. 
 
 
UCSD Principal  Investigator / Study  Chair  
  
 
Printed  Name  
  
 
Signature Date  
 
 
  
Participating  Site Principal Investigator 
  
 
Printed  Name  Institution  
  
 
Signature Date  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 6.0 
Protocol  Date: December 03, 2021  
  Page  4 of 45  
 TABLE OF CONTENTS  
STUDY SCHEMA  ........................................................................................................................ 6 
......................................................................................................................................................... 6 
STUDY SUMMARY  ..................................................................................................................... 7 
1.0 INTRODUCTION ........................................................................................................ 11 
2.0 BACKGROUND AND RATIONALE  ....................................................................... 11 
2.1 Immunotherapy  in HNSCC  ........................................................................................................................ 11 
2.2 Study Agent  ............................................................................................................................................... 12 
2.2.1  IPI-549 12 
2.2.2 Summary  of Pharmacology  of IPI-549 12 
2.2.3 Rationale  for IPI- 549 as  a Potential Therapy  for Patients  with Cancer  12 
2.3 Rationale  .................................................................................................................................................... 13 
3.0 STUDY OBJECTIVES  ................................................................................................ 13 
3.1 Primary  Objectives ..................................................................................................................................... 13 
3.2 Secondary  Objectives  ................................................................................................................................. 14 
3.3 Endpoints  ................................................................................................................................................... 14 
3.4 Primary  Endpoints  ..................................................................................................................................... 14 
3.5 Secondary  Endpoints  ................................................................................................................................. 14 
3.6 Exploratory  endpoints  ................................................................................................................................ 15 
4.0 PATIENT  ELIGIBILITY  ........................................................................................... 15 
4.1 Inclusion Criteria  ....................................................................................................................................... 15 
4
.2 Exclusion Criteria  ...................................................................................................................................... 16 
5.0 TREATMENT PLAN  .................................................................................................. 17 
5.1 Study Design  .............................................................................................................................................. 17 
5.2 Treatment  Dosage and  Administration  ...................................................................................................... 17 
5.3 Duration  of Study  Treatment  ..................................................................................................................... 17 
5.4 Duration  of Follow  Up ............................................................................................................................... 17 
5.5 Discontinuation from  Study  Participation  .................................................................................................. 17 
6.0 STUDY PROCEDURES .............................................................................................. 18 
6.1 Definitions  of Study  Assessments  .............................................................................................................. 18 
6.1.1 Medical  history  18 
6.1.2 Review  subject  eligibility  criteria  18 
6.1.3 Concomitant medications  18 
6.1.4 Physical  exam  18 
6.1.5 Adverse  event  assessment  18 
6.1.6 Clinical Laboratory  Tests 18 
6.1.7 ECG  18 
6.1.8 Tumor  Biopsy  and Research Blood Collection  19 
6.2 Screening/Baseline  Procedures  .................................................................................................................. 22 
7.0 ADVERSE  EVENTS .................................................................................................... 22  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 6.0 
Protocol  Date: December 03, 2021  
  Page  5 of 45  
 7.1 Adverse  Event Monitoring  ......................................................................................................................... 23 
7.2 Severity  ...................................................................................................................................................... 23 
7.3 Seriousness  ................................................................................................................................................ 24 
7.4 Relationship  ............................................................................................................................................... 25 
7.5 Prior experience  ......................................................................................................................................... 25 
7.6 Reporting Requirements  for Adverse Events  ............................................................................................. 25 
7.6.1 Expedited  Reporting  25 
7.6.2 Routine  Reporting  Requirements  26 
8.0 AGENT  INFORMATION ........................................................................................... 26 
8.1 Agent  IPI-549 ............................................................................................................................................ 26 
9.0 STATISTICAL  CONSIDERATIONS  ....................................................................... 28 
9.1 Study Design/Study  Endpoints  .................................................................................................................. 28 
9.2 Sample  Size and  Accrual  ........................................................................................................................... 28 
10.0 STUDY MANAGEMENT  ........................................................................................... 29 
10.1 Conflict of Interest  ..................................................................................................................................... 29 
10.2 Institutional Review  Board  (IRB) Approval and  Consent  ......................................................................... 30 
10.3 Subject  Data Protection  .............................................................................................................................. 30 
10.4 Data  and Safety  Monitoring/Auditing  ........................................................................................................ 30 
10.5 Adherence to the Protocol  .......................................................................................................................... 31 
10.
6 Amendments  to the Protocol  ...................................................................................................................... 31 
10.7 Record Retention  ....................................................................................................................................... 31 
11.0 ETHICAL  CONSIDERATIONS  ................................................................................ 32 
11.1 Ethical Conduct of  Study  ........................................................................................................................... 32 
11.2 Subject  Data Protection  .............................................................................................................................. 32 
12.0 REFERENCES  ............................................................................................................. 33 
13.0 APPENDICES  .............................................................................................................. 34 
Appendix A.  Performance Status  ............................................................................................................................ 34 
Appendix  B: Patient Pill Diary  [be sure to bring  this diary  and pill bottles with  you to your next study  visit.  ....... 36 
Appendix  C: Medications  or foods  known to inhibit or induce CYP3A  ................................................................. 37 
Appendix  D: Medications  associated  with prolongation  of the QTC  and/or  with torsades  de pointes  .................... 39 
Appendix  E: CYP2C8  OR CY2C9  SUBSTRATES ................................................................................................ 41 
Appendix  F: P-GP Substrates  and medications  that are inhibitors  of P-GP ............................................................ 42 
Appendix G: Pharmacodynamic changes observed in peripheral blood of MARIO3 TNBC  patients after 15  
day treatment  with  eganelisib  in combination  with  atezolizumab  + nab-paclitaxel 
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  6 of 45  
 
UCSD  Moores  Cancer  Center  CONFIDENTIAL  
Phase  2 Window  Study of IPI-549 in  Locally  Advanced HNSCC  
 
 
 
STUDY  SCHEMA  
 
   
• Baseline tumor 
measurement  
• Tumor biopsy (non-  
Patients  with  Locally  
Advanced, Previously 
Untreated HNSCC Amenable 
to Surgical Resection  
 
Therapy : 
 
IPI-549 40 mg  QD*  PO 
days 1-14 
 
 
2 weeks  
 
 
Surgical  Tissue  Specimen  
 
 
  
 
Standard Therapy  
Survival,  Toxicity  Follow- Up 
*Final dose based on ongoing Phase 1 study 
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  7 of 45  
 [[STUDY_ID_REMOVED]] 
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  8 of 45  
 UCSD  Moores  Cancer  Center  CONFIDENTIAL  
Phase  2 Window  Study of IPI-549 in  Locally  Advanced HNSCC  
 
 
 
STUDY  SUMMARY  
 
 
Title  Phase  2 Window  Study  of IPI-549 in Patients  with Locally  Advanced  HPV+  or 
HPV- Head  and Neck  Squamous  Cell Carcinoma  
Short  Title  Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  
Phase  2 
Methodology  Single  arm, unblinded 
Study Duration  2 years  
Study  Center(s)  University of California,  San Diego  
 
 
Objectives  1. To detect  a change  in the PI3Kgamma  regulated  gene  expression  signature  
of immune  suppression.  
2. To detect  change  in myeloid,  T cell  composition  and immune  activation  
markers  by IHC as well as  TCR sequencing  
3. To determine safety and tolerability of IPI -549 and change in tumor size in  
patients  with locally  advanced HNSCC.  
Number  of Subjects  15 
Diagnosis  and Main  
Inclusion  Criteria  Eligible  patients  (n=15)  with pathologically  confirmed  locally  advanced,  
previously  untreated HNSCC that  is amenable to surgical  resection.  
 
Study  Product(s), Dose,  
Route, Regimen  IPI-549, 40  mg QD PO* 
 
*Final dose based on ongoing Phase 1 study 
[[STUDY_ID_REMOVED]]  
Duration  of administration  At least  14 days  
Reference therapy  N/A 
 
 
 
Statistical Methodology We anticipate  enrolling  15 subjects.  Within  subject  change  from  the post-treatment  
to the pre-treatment  sample  in the immune  activation  signature  will be the primary  
endpoint. We will test the hypothesis of an increase in this signature using a one  
sided paired t -test at 5% significance level. With 15 subjects we have 80% power 
to detect  a difference in the mean  signature  equal  to 0.68 standard  deviations.  
 
A safety stopping rule will halt the study if at any time 3 or more subjects have  
observed progression  prior  to surgery.  
 
 
     
 
    
 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  9 of 45  
  
SCHEDULE  OF EVENTS  
 
Procedure  Screen/  Baseline  
(≤ 28 days) Window of  
Opportunity  
Week 1 Day 1 
(±3 days)  Pre-Surgery10 
Week 2 Day 14 
(±3 days) Follow -up 
 
Approximately  30 days  ( ±7 
days)after last dose of study  
drug 
Informed  Consent  Within  28 days     
Eligibility  X    
Medical  History  X    
Demographics  X    
Concomitant Medications  
Assessment  X X X X9 
Adverse  Event  Assessment   X X X9 
Physical  Exam1 X X X X 
Vital Signs  and Height  X  X X 
ECOG  PS X  X X 
CBC  with Diff2 Within  7 days  X X X 
CMP3 Within  7 days  X X X 
Pregnancy  test4 Within  72 hours     
HIV (as clinically  indicated)  X (Within  7 days)     
HEP B & C (as clinically  indicated)  X (Within  7 days)     
ECG  (12-lead)  X    
Tumor  tissue  collection5 X  X11  
Blood  Collection  for Correlative  
studies6 X(Within  7 days)  X  
MRI or CT (neck  & chest)     X7 
IPI-549 administration8  X   
Safety  follow  up    X 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  10 of 45  
  
 
IPI-549 is 14 days  in length  with the last administration  within  24 hours of surgery. 
 
1. Full physical  exam  at baseline;  targeted  physical  exam  at other  time points. 
2. CBC  with Diff:  Complete  blood count with differential.  
3. CMP: Comprehensive metabolic panel (bicarbonate, calcium, chloride, creatinine, glucose, potassium, sodium BUN, albumin, 
bilirubin  total, alkaline  phosphatase, total protein, ALT,  AST).  
4. Pregnancy  test for females  of child -bearing  potential only. 
5. Tumor tissue  collection: See Section  6.1.8 for specifications.  
6. Blood for correlative studies should be collected at the same time blood is drawn for CBC and CMP if possible. 40 mL blood to be 
collected  at baseline; 30 mL blood to be collected at pre-surgery visits. See  Section 6.1.8. 
7. Scans  will be performed  when  clinically  indicated.  
8. IPI-549 administration  (Section  5.2): administered  PO 40 mg  QD until 24 hours prior to date when  surgery is performed. Not  
allowed  less than 24 hours of surgery.  
9. In Follow -Up period, concomitant medications will be collected at Safety Follow-Up visit (approximately 30 (+7) days after the 
last dose of study drug) and for SADs. During this period, adverse events will be collected at Safety Follow-Up and SAEs until 90 
days after  last does of study drug.  
10. Surgery  is to be performe d no later  than 48 hours after  last dose of therapy.  Therapy  should continue until the day before surgery. 
11. Tumor tissue  collection to  occur  during surgery.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in  Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  11 of 45  
  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  12 of 45  
  
1.0 INTRODUCTION 
This protocol proposes to examine the anti -tumor efficacy of IPI -549 in patients with  
locally  advanced  HPV+ or  HPV- HNSCC.  Subjects  who are candidates  for surgical  resection  will 
be enrolled and treated with IPI -549 for 2 weeks prior to surgery. Tumor tissue for research  
purposes will be obtained by core biopsy prior to treatment and at surgery after 2 weeks of  
treatment.  Tissue  will be evaluated  by RNA  profiling  for two PI3Kγ -regulated  immune  
suppression signatures  that we previously identified;  changes  in immune  responses will be 
validat ed by performing immunohistochemistry to detect myeloid and T cell composition and 
activation  status  and by genomic sequencing to detect  changes  in intra-tumor T cell receptor  (TCR)  
clonality.  
 
 
2.0 BACKGROUND AND  RATIONALE  
 
2.1 Immunotherapy  in HNSCC 
Immune therapy  holds great  promise  for the treatment  of cancer  patients,  as novel 
immunotherapeutic agents  such as the checkpoint inhibitors pembrolizumab and nivolumab (anti- 
PD-1) have recently demonstrated potent  anti-tumor activity in  a subset of cancer patients.  
Disappointingly, clinical  responses to these  checkpoint inhibitors occurred  in only 20% of patients  
with head and neck squamous cell carcinoma (HNSCC), a devastating disease that is associated  
with considerable morbidity and  mortality.  Improved t herapeutic  approaches  that target  the 
mechanisms of immune escape from checkpoint inhibitors could hold great promise for patients  
with HNSCC and other cancers. Recent studies from our lab and others show that immune  
suppressive Tumor Associated Macrophages (TAMs) and Myeloid Derived Suppressor Cells  
(MDSCs) promote escape from checkpoint inhibitors. Signals from the tumor microenvironment  
polarize these myeloid cells towards an immunosuppressive phenotype that is characterized by  
high levels  of A rginase,  TGFß,  IL10  and low levels  of MHCII,  IL12,  iNOS  and T cell 
chemoattractants such as CXCL9 and CXCL10. TAMs and MDSCs then suppress CD8+ T -cell 
recruitment, survival, and cytotoxic function, thereby inhibiting effective anti -tumor immune  
responses. Novel immune therapeutics that circumvent resistance to checkpoint inhibitors could  
provide benefit to numerous cancer  patients, including patients with HNSCC.  
We recently  identified  a novel pathway by which  TAMs  and MDSCs  inhibit 
responsiveness to checkpoint inhibitors [1, 2]. We found that phosphatidylinositol-4,5- 
bisphosphate 3- kinase gamma (PI3Kγ), a myeloid cell selective isoform of PI3 -Kinase, mediates  
immune suppression in TAMs and MDSCs by inhibiting NFkB activation and promoting mTor,  
S6K and c/EBPß activation, thereby leading to transcription of immune suppressive factors that  
inhibit T cell responses to tumors. Our results demonstrated that PI3Kγ, the major PI3K isoform  
in myeloid  cells,  promotes resistance to checkpoint inhibitors and stimulates  tumor progression as 
selective inactivation  of PI3Kγ  suppressed myeloid  cell expression  of immune  suppressive factors  
and inhibited  tumor progression in mouse models of HNSCC,  lung, breast,  and pancreatic 
carcinoma, as well as melanoma and glioblastoma. Importantly, PI3Kγ inhibition stimulated  
responses to checkpoint inhibitors, leading to eradication of tumors and long -term anti-tumor 
immunological memory  in mouse models of HNSCC.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  13 of 45  
 Importantly, we also identified  a PI3Kγ -regulated  gene expression  signature that is 
associated  with outcome  in HNSCC  and lung cancer  patients.  Notably, high expression of a PI3Kγ - 
regulated immune suppression signature was associated with decreased patient survival in these  
patients. Conversely, low expression of this signature was associated with extended survival in 
these patients.  These results  suggested  that a PI3Kγ -regulated  immune  suppression signature could 
be used to identify cancer patients who are candidates for PI3Kγ inhibitor therapy and to monitor  
clinical  responses to P I3Kγ -inhibitors. 
 
2.2 Study  Agent  
2.2.1  IPI-549 
The PI3K -γ isoform plays important roles in immune cell function and migration, including the  
immune suppressive tumor microenvironment. IPI -549 is a potent and selective PI3K - γ inhibitor  
that is being developed  by Infinity Pharmaceuticals, Inc. (Infinity) as an orally administered  
potential therapeutic in  multiple  cancer  indications. 
2.2.2 Summary  of Pharmacology  of IPI -549 
Biochemical, cellular, and receptor binding assays showed that IPI -549 is a potent inhibitor of  
PI3K -γ that is highly selective over other protein and lipid kinases, GPCRs, ion channels, and 
transporters.  Cellular  proliferation  assays demonstrated  that IPI-549 does not have a direct  growth 
inhibitory effect  on human  solid  tumor cells lines.  In vitro  functional assays  demonstrated  that IPI- 
549 blocks bone marrow  derived  murine  myeloid  cell polarization  to the M2 macrophage 
phenotype in response to IL-4 and macrophage colony- stimulating  factor,  and macrophage  
migration towards CXCL12, but does not inhibit Concanavalin A -induced T cell activation as  
measured by IFN -γ production. These data indicate the potential for IPI -549 to block immune  
suppressive macrophage development but not certain T cell activities that are important for the  
anti-tumor effect mediated by  cytotoxic  T cells.  
The effect of IPI -549 on tumor growth was evaluated in vivo using immune competent,  
murine syngeneic solid tumor models. Mice treated with IPI -549 demonstrated significant tumor  
growth inhibition in multiple syngeneic models.  Tumor growth inhibition was dose -dependent 
with dose-proportional plasma  and tumor exposure for IPI-549. Studies to elucidate the mechanism  
of tumor growth  inhibition  indicated  that IPI-549 affects  immune -suppressive myeloid  cell 
numbers and/or function, leading to an increase in cytotoxic T cell activity. Studies in both nude  
and CD8 T cell -depleted mice demonstrated the T -cell-dependence of IPI -549 mediated tumor  
growth  inhibition. 
2.2.3 Rationale  for IPI-549 as a Potential Therapy  for Patients with Cancer  
PI3K -γ is expressed  in immune  cells and has limited,  if any, expression  in epithelial cancer  
cells. Furthermore, PI3K -γ is the predominant catalytic isoform found in myeloid cells [2]. In 
myeloid  cells PI3K -γ is activated  by GPCRs,  the Toll Like Receptors/Interleukin 1 Receptors  and 
RTKs  [2]. The role of myeloid  cells in promoting tumor growth  has been  demonstrated in multiple  
preclinical mouse models [3]. Tumors and their associated stroma secrete chemokines that attract  
precursor monocytes that differentiate into macrophages. The tumor associated macrophages as  
well as dendritic cells and granulocytes (collectively known as myeloid derived suppressor cells  
[MDSC]), actively support the proliferation of the tumor cells while at the same time actin g to 
suppress host antitumor activity  [4]. 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  14 of 45  
 Pre-clinical data from a tumor bearing mouse knockout model of PI3K -γ results in a  
reduced influx of myeloid cells, and reduced vascularization of the tumor, resulting in reduced  
tumor growth, suggesting that PI3K -γ inhibition can play a critical role in disrupting the MDSCs  
[2]. 
The established role of PI3K -γ in the biology of the tumor microenvironment supports  
testing  IPI-549 in patients  with cancer,  both as a single  agent, and in combination  with other drugs.  
The PI3K -γ isoform plays important roles in immune cell function and migration, including the  
immune suppressive tumor microenvironment. IPI -549 is a potent and selective PI3K - γ inhibitor  
that is being developed by Infinity Pharmaceutic als, Inc. (Infinity) as an orally administered  
potential therapeutic in  multiple  cancer  indications. 
 
2.3 Rationale  
HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) are deadly and  
disfiguring cancers with limited therapeutic options; while checkpoint inhibitors have promise as  
new cancer therapeutics, they have demonstrated limited activity in HNSCC. However, we found  
that inhibitors of PI3Kγ, such as Infinity Pharmaceutical’s highly selective inhibitor, IPI -549, 
repolarized tumor associated  macrophages to reverse immune suppression and stimulate anti - 
tumor immunity in animal models of HNSCC. We identified a signature of immune suppression 
in mouse models of HPV+ and HPV - HNSCC that was reversed by PI3Kγ inhibition [5]. Using  
TCGA data, we found that this same signature was associated with poor outcome in HPV+ and  
HPV- HNSCC  patients  [5]. Our results  suggest  that selective  PI3Kγ  inhibitors might  promote anti- 
tumor immune  responses in HNSCC  patients.  We hypothesize  that treatment  with  the selective  
PI3Kγ inhibitor IPI -549 will switch mRNA expression signatures of immune suppression in  
patient tumors to signatures of immune activation. These signatures could then serve as  
surrogate biomarkers  of IPI-549 efficacy.  Therefore,  we propose to establish  a Phase II window 
of opportunity clinical trial to evaluate the effect  of IPI-549 on biomarkers of immune  suppression. 
Patients with resectable HNSCC will be treated with the investigational, highly selective PI3Kγ  
inhibitor IPI -549 for two weeks  prior to surgical resection; pre - and post -treatment biopsies will  
be evaluated  for changes  in the PI3Kγ -responsive gene  expression  signature of immune  
suppression we previously identified. Additionally, we will monitor for changes intratumoral and  
circul ating immune cell populations in collaboration with Dr. Lisa Coussens, OHSU, using  
multiplex  immunohistochemistry.  These studies will be useful in identifying  biomarkers of 
response that will allow  optimization  of future  therapeutic strategies  for HNSCC.  
 
3.0 STUDY  OBJECTIVES  
This is a phase 2 window of opportunity trial in patients  with locally  advanced  HNSCC.  A 
key objective is to provide the first proof that macrophage phenotype switching  can be 
accomplished  in humans and lay the groundwork for future  trials  of this novel approach  to immune  
therapy. Subjects who are candidates for surgical resection will be enrolled and treated with 2  
weeks of IPI -549, a specific PI3Kγ inhibitor. Tumor tissue for research purposes through core  
biopsies will be  obtained prior to initiation of IPI -549 and at surgery. 
 
3.1 Primary  Objectives  
1. To detect IPI -549-induced changes in PI3Kγ -regulated  signatures of immune suppression.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  15 of 45  
 3.2 Secondary  Objectives  
1. To measure changes in myeloid and T cell composition and activation status by  
immunohistochemistry  and TCR sequencing.  
2. To determine  safety  and tolerability  of IPI-549 and change in tumor size in patients  
with locally  advanced  HNSCC.  
3. To measure changes  in peripheral  cytokines and  immune  cells 
 
3.3 Endpoints  
 
We hypothesize that mRNA signatures of immune response will be increased in IPI -549- treated  
HNSCC  patients.  For the efficacy  endpoints, RECISTv1.1 will be used. 
 
Primary  Endpoints  
 
We hypothesize that the 5 -gene mRNA immune response signature from Kaneda et al. [2] will 
increase with treatment.  
 
Specifically,  the signature  is: s= IL12A + IL12B + IFNG  + CD8A  – IL6, measured  by RNA  
expression  levels from a custom Nanostring Immune  Profiling  panel.  
 
Secondary  Endpoints  
 
1. Adverse events  related  to IPI-549 (description, grade  [CTCAE  v5.0], and seriousness).  
2. T cell receptor  (TCR)  sequencing from  blood obtained at  baseline,  surgery,  end of treatment  
or at time  of disease progression. 
3. Comparison of pre- vs. post-treatment tumor tissue for CD8 expression by 
immunohistochemistry  
4. Comparison of pre- vs. post- treatment  peripheral cytokines  and immune  cells.  
 
We hypothesize that the 42- mRNA signature of PI3Kγ [2] will increase with treatment. Gene  
expression  will be  assessed by  Nanostring custom panel.  
Specifically, the signature is comprised of the sum of 21 immune response and T -cell 
activation genes, plus the sum of 10 antigen presentation genes, minus the sum of 11 immune  
suppression genes [2]  listed below. 
Gene lists for the PI3Kgamma activation  signature are:  
• Immune  suppression genes:  PDGFA PDGFB  HBEGF  PLAU  F3 IFIT1  
CD276 IL6 CCL7 CCL4  ID2 
• I mmune response, T cell activation genes: IER3 ADORA2A CCR7 RASGRP1 CXCR3  
CX3CR1  IL12B IL12A CD4  CD8A  CD8B  GZMA GZMK  GZMH  GZMM IFNG  CD28, 
LAT LAG3  ZBP1  BTLA  MALT1  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  16 of 45  
 • Antigen presentation genes:  
HLA_DMA  HLA_DMB  HLA_DRB5  HLA_DOB  CIITA 0 HLA_DQA2 HLA_DRA  
HLA_DOA  HLA_DQB2  CD74. 
Exploratory endpoints  
 
 
Three IHC panels  to assess myeloid and T cell content  and activation states,  each  panel  is 
expected  to increase with  treatment  
• Lymphoid panel:  PD-1, CD3,  RORgt,  CD56, CD8,  Tbet,  GATA3,  FoxP3  PD-L1, CD20, 
CD45, p16 
• Myeloid panel: Tryptase, CD68, CSF1R, DC-SIGN, CD66b, CD83, CD163, MHCII, PD- 
L1, CD3/20/56, CD45, p16 
• T cell activation  panel:  CD3,  CD4,  CD8,  IDO,  Tbet,  CD68, PD-1, Eomes,  Ki67, Granzyme  
B, CD45  
 
4.0 PATIENT  ELIGIBILITY 
 
4.1 Inclusion  Criteria  
Subjects  must meet  all of the inclusion criteria  to participate  in this study.  
1. Patients  must have locally  advanced,  previously untreated HNSCC (unknown primary or 
any primary site except cutaneous or EBV- related nasopharynx cancer) that is amenable 
to surgical resection  
2. Age 18 years  or older 
3. Patients  must be able to  administer IPI -549 by mouth  and have no evidence of 
malabsorption 
4. Patients  must be able to undergo a core tumor biopsy with tissue  available for analytics  
 
5. There must be at  least 2 weeks  between  initiation  of IPI -549 and surgical  resection  
6. ECOG performance status  0-2 
7. Patient  has adequate organ  function as  defined  below: 
 
Test Name  Laboratory  Value  
Absolute  Neutrophil  
Count  ≥ 1.0 x  109/L 
Platelet  count  ≥ 75 x 109/L (transfusion  independent  for > 7 days)  
Hemoglobin ≥ 8.0 g/dL (may  receive transfusions) 
Total  bilirubin  ≤ 1.5 x institution’s  upper limit of normal (ULN)  
AST  and ALT  ≤ 2.5 X institutional upper limit of normal 
Serum  creatinine  ≤ 1.5 x institution’s  ULN,  or creatinine  clearance ≥  60 ml/min  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  17 of 45  
 8. Female patient of childbearing potential has a negative serum or urine pregnancy within 7 
days prior to receiving  the first dose  of study medication.  
9. Female patient of childbearing potential agrees to use 2 methods of birth control or be 
surgically sterile, or abstain from heterosexual activity for the course of the study through 
120 days  after the last dose of study medication.  
Note: Females of childbearing potential are those who have not been surgically sterilized or have not been free from  menses for  > 1 year.  
 
10. Male patient with a partner of childbearing potential agrees to use an adequate method of  
contraception starting with the first dose o f study therapy through 120 days after the last dose 
of study therapy.  
 
4.2 Exclusion  Criteria  
Subjects  meeting  any of the exclusion  criteria  at baseline  will be excluded  from  study participation.  
Subjects  are to  be excluded from  the study if they meet  any of the following  criteria:  
 
1. Cutaneous squamous cell carcinoma  (SCC)  or Epstein -Barr virus (EBV)  related  nasopharynx cancer  
2. Severe allergic  or anaphylactic reaction  to IPI-549. 
NOTE:  Subjects with  a history of anaphylaxis  to other agents are eligible  for study participation. Subjects  
who have  received  alternative  therapies,  including  prior IPI -549, are  eligible  for study  participation  
3. Major  surgery  within 4 weeks prior to initiation of  study drug 
4. Subjects  who have  been  treated  with chemotherapy,  biologic therapy,  or other investigational  agent  
within  < 5 times the half -life of the agent or < 28 days (whichever is shorter)  of starting  study drug 
5. Infection with human immunodeficiency virus  (HIV),  hepatitis  B, or hepatitis  C virus  (HCV)  
6. Ongoing treatment  with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids  
7. Ongoing systemic bacterial,  fungal, or viral  infections at Screening  
NOTE:  S ubjects  on antimicrobial,  antifungal, or antiviral prophylaxis  are not specifically  excluded  if all 
other inclusion/exclusion criteria are met  
8. Administration  of a live vaccine within  6 weeks of first dose  of study drug 
9. Administration  of any of the following within  2 weeks prior  to the administration  of study drug:  
a. Strong inhibitors  or inducers of CYP3A4,  including  grapefruit, grapefruit  juice  and herbal  
supplements 
b. P-glycoprotien (P-gp) inhibitors  
c. Warfarin,  phenytoin, or other  substrates of CYP2C8  or CYP2C9  with a narrow therapeutic range  
d. Medications associated  with QTc  interval  prolongation or Torsades de Pointes  
10. Baseline QT interval  corrected  with Fridericia’s  method (QTcF)  > 480 ms (average  of triplicate  
readings)  
11. Prior  surgery or gastrointestinal  dysfunction that may affect  drug absorption  (e.g. gastric  bypass surgery,  
gastrectomy)  
12. Female subjects who are pregnant  or breastfeeding  
13. Concurrent active  malignancy  other than nonmelanoma skin cancer,  carcinoma  in situ of the cervix,  or 
prostate intraepithelial neoplasia 
14. History  of peptic  ulcer  and/or gastrointestinal  bleed  that have  not resolved  
15. Unstable or severe uncontrolled medical  condition (e.g., unstable cardiac function, unstable pulmonary 
condition including  pneumonitis and/or interstitial lung disease,  uncontrolled diabetes)  or any important 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  18 of 45  
 medical  illness  or abnormal laboratory findin g that would, in the Investigator’s  judgment, increase  the risk 
to the subject  associated with his or  her participation  in the study. 
 
 
5.0 TREATMENT PLAN  
 
5.1 Study  Design 
This is a phase 2 window of opportunity trial in  patients  with locally  advanced  HNSCC.  Subjects  
who are candidates for surgical resection will be enrolled and treated with 2 weeks of IPI-549, a 
specific PI3Kγ inhibitor. Tumor tissue for research purposes through core biopsies will be  
obtained prior to initiation of IPI -549 and at surgery. 
 
5.2 T reatment  Dosage  and Administration  
 
IPI-549 will be administered 40 mg orally over a 14 day cycle. Dose of IPI -549 will be determined  
based on observed toxicity in ongoing Infinity clinical trial ([STUDY_ID_REMOVED]). IPI -549 should be self - 
administered orally (approximately every 24 hours). IPI -549 should be swallowed whole with a glass  
of water  (approximately  8 ounces or 240 mL).  Subjects must  avoid  grapefruit and grapefruit juice  while 
on study drug. Subjects should be advised  to avoid  food and liquids  other than water  from 2 hours prior 
to dosing until 1 hour after dosing. 
 
5.3 Duration  of Study  Treatment  
IPI-549 for 2 weeks prior to surgical resection. Subjects will be monitored continuously for toxicity 
while on study therapy. Toxicity will be assessed using the NCI -CTCAE, v. 5.0 or higher. There will  
be no dose modification  allowed  on study.  Missed  doses should be recorded  on the pill diary.  Any 
grade 3 toxicity will result in discontinuation of IPI -549. If at any time 3 or more subjects have 
observed progression prior to  the start of  definitive  treatment  the study will be halted.  
 
5.4 Duration of Follow  Up 
All subjects will have a Safety Follow -up visit approximately 30 (+ 7) days after the last dose of  
study drug. At minimum this visit should include collection of AEs/SAEs and concomitant  
medications/procedures. This will be a clinic visit. The following activities will be performed  
during the visit,  assessment  of concomitant medications,  adverse events,  physical  exam,  vital signs  
and height, ECOG PS, CBC with differential, CMP . MRI or CT scan will be performed if  
clinically  indicated.  
 
 
5.5 Discontinuation  from  Study  Participation  
Patients may be removed from study participation for the following reasons (in  addition to those 
listed  for discontinuation of study treatment):  
• The patient  or legal  representative withdraws  consent for follow-up; 
• The patient  is lost to follow-up; 
• The patient  dies;  
• It is the decision of the investigator.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  19 of 45  
 • Severe allergic  or anaphylactic reaction  to IPI -549 
• Disease progression prior to surgery 
• Pregnancy  
• Severe or life-threatening toxicity  
6.0 STUDY  PROCEDURES  
Refer  to the study Schedule of Events for procedures.  
 
All patients  will be closely  monitored for safety  and tolerability  during all cycles  of therapy, at  
study treatment completion/early study treatment discontinuation, and during the follow-up 
period. 
 
6.1 Definitions  of Study  Assessments  
6.1.1 Medical  history  
A complete medical, surgical and oncology history as well as history of infections are  
obtained at screening. Any changes from Screening (e.g. worsening severity or abnormal  
findings) are  considered to be adverse events  (AEs).  
6.1.2 Review subject  eligibility  criteria  
Review  of eligibility  criteria  as described  in Section  3 to ensure subject  qualification  for 
study entry.  
6.1.3 Concomitant  medications 
At Screening, concomitant/previous medications and procedures will be assessed including 
all medications/procedures that have  occurred since  the last visit.  
6.1.4 Physical  exam  
A full physical exam  (PE) will be performed at Screening and will include  vital signs  
(temperature, blood pressure [sitting for 5 minutes], pulse rate, and respiratory rate), height,  
and weight. If vital signs need to be repeated during a single visit, assessments should be  
conducted  approximately  5 minutes apart.  Subsequent exams  may be directed  as appropriate. 
6.1.5 Adverse event  assessment  
Baseline assessment of subject status for determining adverse events. See Section 7 for  
Adverse Event monitoring and reporting. 
6.1.6 Clinical Laboratory  Tests 
Blood chemistry,  hematology,  and βhCG  pregnancy tests will be  administered  throughout the 
study to monitor safety. 
6.1.7 ECG  
At the treatment  termination  visit,  a standard  12-lead ECG  will be conducted following an  
approximate 10- minute  rest period and obtained in triplicate within approximately a 5 - 
minute  time period. QTc measurements  will use the Fridericia’s  correction  method (QTcF).  
ECGs  will be  read locally  by the Investigator. Tumor  assessment  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  20 of 45  
 6.1.8 Tumor  Biopsy  and Research Blood  Collection  
Tumor tissue  will be obtained by core biopsy prior to treatment  and at surgery after 2 weeks  
of treatment. The goal of the planned laboratory correlative studies is to further characterize the  
biology of PI3K γ inhibition, to gain a better understanding of the impact of IPI -549 on the tumor  
microenvironment, and  explore potential biomarkers. See Section 3 for further details.  
 
6.1.9 Research  Sample  Collection  Guidelines  
Specimens  should be collected  as outlined below and ALL  samples  should be labeled  with the 
following: 
• Protocol number 
• Institution  
• Patient’s  de-identified  study number 
• Date of biopsy or surgery 
 
6.1.9.1  Tumor  tissue  from  initial biopsy  
Tumor tissue  will be collected  from  a diagnostic core biopsy preferably  performed  within  28 days 
of initiating  study treatment.  
 
When  possible, 4 core biopsies should be taken  for lesions > 1.5 cm, otherwise 2 cores  should be 
taken.  
• If 4 cores  are obtained, 1 core should be fresh  frozen  and the rest  should be formalin -fixed  
paraffin  embedded  (FFPE).  
 
• If < 4 cores are obtained, tissue for research should be FFPE after being divided into the  
research  and diagnostic documentation blocks according  to the Pathology staff’s  
specifications.  
 
Ten (10) unstained sections  (4-5 micron  slices)  or one (1) 20 micron  roll-ups from  FFPE  tissue  are 
desired.  
 
Fresh  frozen  samples  should be stored  in liquid  nitrogen and FFPE  samples  at room temperature 
until shipment.  
 
6.1.9.2  Tumor  tissue  from  surgical  resection  
Tumor tissue  for research  will be collected  from  only material in excess  of that needed for  routine 
clinical  care as determined by  a staff  pathologist. 
 
Depending on the amount of tissue  available,  tissue  should be collected  for research  in the 
following order  of preference:  
1. Ten (10) unstained sections (4-5 micron  slices)  and one (1) 20 micron  roll-ups from  FFPE  
tissue.  
2. 10 unstained sections  from  fresh  frozen  tissue.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  21 of 45  
 Fresh frozen samples should be stored in liquid nitrogen and FFPE samples at room temperature  
until shipment. 
 
6.1.9.3  Peripheral  Blood Mononuclear Cells  (PBMCs)  
Blood for PBMCs will be collected prior to study treatment at screening (may be collected at the  
same time as blood drawn for routine laboratory tests)  and at the time  of surgery.  
 
Blood samples will be  collected in two heparin green top tubes (approximately 20 ml). Samples  
should be processed the day of collection according to the PBMC isolation protocol in the  
Laboratory  Manual.  
 
PBMCs  should be stored  at -80°C.  
 
6.1.9.4  Buffy  Coat 
Blood samples  will be collected  in one EDTA  purple top tube (approximately  10 ml) prior to study 
treatment at screening (may be collected at the same time as blood drawn for routine laboratory  
tests).  
 
Samples should be processed the day of collection according to the buffy coat isolation protocol  
in the Laboratory Manual.  
 
Samples  should be stored  at -80°C.  
 
6.1.9.5  Serum  Cytokines 
Blood samples will be collected in one yellow -gold top serum separation tube (approximately  5 
mL) prior to  study treatment  at screening (may  be collected  at the  same time  as blood drawn for 
routine laboratory tests) and at the time of surgery.  
 
Samples  should be processed  the day of collection  according  to the instructions provided below: 
1. Fill tube completely. Invert 5 -6 times and stand upright for a minimum of 30 minutes to 
clot. 
2. Centrifuge within 2 hours at 1000-1300g for 10 minutes at room temperature. 
3. Aliquot into two 2 mL labeled cryovials. 
4. Store samples at -65°C to -85°C.  
5. Ship samples monthly to The Forsyth Institute : 
 
The Forsyth Institute 
c/o Danielle Stephens, MS  
The Forsyth Institute 
245 First St. 
Cambridge, MA 02142 
 
6.1.9.6  Flow  Cytometry  Analysis 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  22 of 45  
 Blood samples will be collected in one purple and black speckled Cyto-Chex tube 
(approximately  5 mL)  prior to  study treatment at screening (may  be collected  at the  same time  as 
blood drawn for routine laboratory tests) and at the time of surgery.  
Samples  should be processed  the day of collection  according  to the instructions provided below: 
1. Fill Cyto -Chex tube completely.  
2. Immediately after collection, invert gently 10 times to ensure proper mixing. 
3. Do NOT  centrifuge. Do NOT  open tube. 
4. Ship ambient with Gel packs on the day of collection to Primity Bio: 
 
Primity Bio  
C/O Erika O’donnell  
48383 Fremont Blvd, Suite 118 Fremont, CA 94538 USA 
 
5. Email package tracking information to: 0109@primitybio.com 
 
6.1.10  Specimen  Handling  
Sample  handling and storage will be  coordinated by 
Sharmeela Kaushal  
Moores Cancer  Center,  3345/3G, GG 
3855 Health Sciences Drive 
La Jolla,  CA 92093-0819 
Phone: 858-822-7661 
 
6.1.11  Specimen  Banking  
Patient samples collected for this study will be retained in the UCSD Moores Cancer Center  
Biorepository for analysis  and future  cancer  research.  Specimens  will be stored  indefinitely  or until 
they are used up. Samples will be labeled with the protocol number, subject’s de -identified study  
number and collection date. The link between study number and medical record number will be  
viewed  over a password secured  encrypted  server -client.  
 
The study research coordinator at each local site will review their subject's medical record for  
demographic and clinical information  pertaining  to the subject's  general  medical  history, 
diagnosis, and outcomes of any treatments received. This information will be transmitted to and retained by the Coordinating  Site UCSD. Samples and data extracted from the subject's medical  
record will be coded with a de -identified study number so that the subject's name and identifying  
information will be removed. A log that links the subject's  name and identifiers  to the study number 
will be maintained in a secure database distinct from the secure database into which the subject's  
clinical  information will be  entered by  study personnel. 
 
Dissemination of specimens for research is at the discretion of the Study Chair, Dr. Cohen. Potential research collaborators outside of UCSD who approach the Moores Cancer Center for  
clinical specimens will be required to complete an agreement (Material Transfer Agreement or  
recharge agreement)  stating  that the specimens  will only be released  for use in disclosed  research,  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  23 of 45  
 and any specimen  left over from  research  will either  be returned  to the Cancer  Center  or destroyed.  
Any data obtained from  the use of clinical  specimen  will be the property of UCSD for publication 
and any licensing agreement will be strictly adhered to. These outside collaborators may include  
for-profit biotechnology corporations interested in collaborating with UCSD investigators in 
research  diagnostic, prognostic assays and drug development. 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  24 of 45  
 The specimens,  DNA,  and their derivatives  may have significant therapeutic or commercial  value.  
The Informed Consent form contains this information and informs the subject that there is the  
potential for financial gain  by UCSD,  the investigator  or a collaborating researcher  or entity.  
 
If patients later decide they do not want their specimens collected to be used for future research,  
they may tell this to the local site principal investigator, who will inform the Study Chair Dr.  
Cohen. Dr. Cohen will use his best efforts to stop any additional studies and to destroy the  
specimens. Samples stored in the Biorepository will be destroyed; for samples that have been  
disseminated outside of the Biorepository, Dr. Cohen will contact the recipient to notify them of  
the need to halt further research  and destroy specimens.  
 
6.2 Screening/Baseline  Procedures 
Assessments performed exclusively to determine eligibility for this study will be done only after  
obtaining informed consent. Assessments performed for clinical indications (not exclusively to  
determine study eligibility) may be used for baseline values even if the studies were done before 
informed  consent was obtained. 
 
All screening procedures must be performed within 7 days prior to registration unless otherwise stated.  The screening  procedures include:  
• Written  informed  consent  (within  28 days) . 
• Review  of inclusion and exclusion criteria.  
• Complete  medical/oncology history. 
• Demographics. 
• Documentation of concomitant  medications.  
• Complete  physical examination,  including vital signs and height. 
• Performance  status  assessment.  
• Laboratory  tests (within  7 days; pregnancy test within  72 hours) . 
• Blood collection  for correlative studies. 
• Documentation of tumor staging.  
• Tumor biopsy tissue  collection  for correlative studies  (within  28 days) . 
 
7.0 ADVERSE EVENTS  
An adverse event (AE) is any untoward medical occurrence in a patient receiving study treatment 
and which  does not necessarily  have a causal  relationship  with this treatment.  An AE can therefore  
be any unfavorable  and unintended sign (including a clinically significant abnormal laboratory  
finding), symptom, or disease temporally associated with the use of an experimental intervention, 
whether  or not related to  the intervention. 
 
Progression  of the cancer  under study or events  which  are unequivocally due to disease progression 
should not be reported as an AE during the study (unless it is considered to be drug related by the 
investigator).  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  25 of 45  
 7.1 Adverse Event  Monitoring 
 
Adverse event data collection and reporting, which are required as part of every clinical trial, are  
done to ensure the safety of subjects enrolled in the studies as well as those who will enroll in 
future studies using similar agents. Adverse events are reported in a routine manner at sch eduled  
times  during a trial.  Additionally, certain  adverse events  must be reported  in an expedited  manner  
to allow  for optimal monitoring  of patient safety  and care.  
 
As far as  possible, each adverse event  should be evaluated  to determine:  
• duration (start  and end dates)  
• severity  (grade) 
• seriousness 
• relationship  to study agent 
• action  taken  (i.e., none, study agent  modification,  medical  intervention) 
• outcome (i.e., resolved  without sequelae,  resolved with sequelae,  ongoing)  
 
Adverse events monitoring begins a t the time of initiating study treatment through 90 days 
following the last administration of study treatment or study discontinuation/termination, or the  
initiation  of new anti-cancer  therapy,  whichever is earlier,  whether  or not related  to IPI -549. 
 
Note:  Serious adverse events must be recorded in the case report forms for this 90 day-period; 
however, non-serious adverse events need only be recorded through 28 days post last study drug administration.  
 
All patients experiencing an adverse event at least possibly  related to study treatment will be  
monitored until:  
 the adverse event  resolves or the symptoms or signs that constitute  the adverse 
event  return to baseline; 
 any clinically  significant abnormal laboratory values  have returned  to baseline;  
 there is a satisfactory  explanation other than the study drug for the changes  
observed; or 
 death.  
 
7.2 Severity  
All non-hematologic adverse events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The CTCAE v5.0 is available at  
http://ctep.cancer.gov/reporting/ctc.html
 
 
If no  CTCAE  grading is available,  the severity  of an AE  is graded as  follows: 
Mild (grade 1):  Mild; asymptomatic or mild symptoms; clinical or diagnostic  
observations only; intervention not indicated.  
Moderate (grade 2):  Moderate; minimal, local or noninvasive intervention indicated; 
limiting  age- appropriate instrumental activities  of daily  living (ADL).  Instrumental ADL  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  26 of 45  
 refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.  
Severe (grade 3):  Severe or medically significant but not immediately life -threatening;  
hospitalization or prolon gation of hospitalization indicated; disabling; limiting self -care 
ADL. Self -care ADL refer to bathing, dressing and undressing, feeding self, using the 
toilet,  taking medications, and not bedridden 
Life-threatening  (grade  4): Life -threatening  consequences; urgent intervention indicated.  
Fatal  (grade  5): Death  related to  AE. 
 
7.3 Seriousness  
A “serious” adverse event  is defined  in regulatory  terminology  as any untoward medical  
occurrence that: 
1. Results  in death.  
 
2. Is life-threatening.  
The patient  was at risk of death  at the time of the event;  it does not refer  to an event  that 
hypothetically  might have caused death if  it were  more  severe.  
3. Requires  in-patient  hospitalization or prolongation of existing  hospitalization. 
Note:  The following  hospitalizations  are not considered  SAEs:  
• A visit to the emergency room or other hospital department < 24 hours 
that does not result  in admission  (unless considered  an important medical  
or life-threatening  event)  
• Elective  surgery,  planned prior to signing consent 
• Admissions as per protocol for a planned medical/surgical  procedure 
• Routine health  assessment  requiring admission  for baseline/trending  of 
health  status (e.g., routine colonoscopy) 
• Medical/surgical  admission  other than to remedy  ill health  and planned 
prior to entry into the study. Appropriate documentation is required in 
these cases.  
• Admission  encountered  for another life circumstance that carries  no 
bearing  on health  status  and requires  no medical/surgical  intervention  (eg, 
lack of housing, economic inadequacy, caregiver  respite,  family  
circumstances,  administrative  reason).  
• Admission  for administration  of anticancer  therapy  in the absence of  any other SAEs.  
 
4. Results  in persistent  or significant disability  or incapacity. 
5. Is  a congenital anomaly/birth defect  
6. Is an important medical  event  
Any event  that does not meet  the above criteria,  but that in the judgment of the investigator  
jeopardizes the patient, may be considered for reporting as a serious adverse event. The  
event  may require medical  or surgical  intervention to prevent one of the outcomes  listed  in 
the definition of “Serious  Adverse Event“.  
For example: allergic  bronchospasm requiring  intensive treatment  in an emergency  room 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  27 of 45  
 or at home; convulsions that may  not result  in hospitalization;  development of drug abuse 
or drug dependency. 
 
7.4 Relationship  
Attribution categories for adverse events in relationship to protocol therapy are as follows:  
Definite  – The AE is clearly  related to the study  treatment.  
Probable – The AE is likely related to the study treatment.  
Possible – The AE may be related to the study treatment.  
Unlikely – The AE is doubtfully related to the study treatment.  
Unrelated  – The  AE is clearly NOT  related to  the study treatment.  
 
7.5 Prior  experience  
Expected  events  are those that have  been  previously identified  as resulting  from  
administration of the agent. An adverse event is considered unexpected, for expedited reporting 
purposes only, when either  the type of event  or the severity  of the event  is not listed  in the current  
known adverse events listed in the agent clinical experience section of this protocol or the current Investigator’s  Brochure.  
 
7.6 Reporting  Requirements for Adverse Events  
 
Serious adverse events, or a follow up to a serious adverse event, including death due to any cause other than progression of the cancer under study that occurs to any subject from the time  
study treatment initiation through 90 days following cessation of treatment , or the initiation of 
new anti-cancer  therapy,  requires  expedited reporting as described below.  
 
7.6.1 Expedited  Reporting  
A. The Study Chair and Site Principal Investigator must be notified within 24 hours of learning 
of any serious adverse events (SAEs)  regardless of attribution, occurring during the  study or  
within  30 days of the last administration of  the study  drug.  
B. The UCSD Human Research Protections Program (HRPP) and Moores Cancer Center 
Data and Safety Monitoring Board (DSMB) must be notified within 10 business days of  
“any  unanticipated problems involving risk to subjects or others” (UPR).  
The following  events  meet  the definition  of UPR:  
1. Any serious event (injuries, side effects, deaths or other problems), which in the 
opinion of the Principal Investigator was  unanticipated,  involved risk to subjects  or 
others, and was possibly related to  the research procedures.  
2. Any serious accidental  or unintentional change to the IRB-approved protocol that  
alters  the level of  risk.  
3. Any deviation from the protocol taken without prior IRB review to eliminate  
apparent  immediate  hazard to a research subject.  
4. Any new information (e.g., publication, safety monitoring report, updated sponsor safety  report),  interim result or other finding that indicates  an unexpected  change 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  28 of 45  
 to the risk/benefit ratio  for the research.  
5. Any breach in confidentiality that may  involve risk to the subject or others. 
6. Any complaint of a subject that indicates an unanticipated risk or that cannot be 
resolved  by the Principal  Investigator. 
C. The FDA  must be not ified by  the Study Chair  according to the following timelines: 
• within 7 calendar days of any unexpected fatal or life-threatening adverse event with 
possible relationship to study drug,  and 
• within  15 calendar  days  of any  event that  is considered: 1) serious, 2) unexpected,  and 3) 
at least possibly related to study  participation.  
7.6.2 Routine Reporting  Requirements  
A. The UCSD HRPP must be notified  of any adverse events  that are not unanticipated  problems 
involving risk to subjects or others (non- UPRs)  at the  time of the annual Continuing Review.  
B. The FDA  must be notified  by the Study Chair  of all non-serious adverse events annually at the 
time of the annual report. 
 
 
 
8.0 AGENT  INFORMATION  
 
8.1 Agent  IPI-549 
Please refer  to Investigator’s  Brochure for more  comprehensive information.  
 
Mechanism  of action (or Product  description):  
 
IPI-549 drug substance is a freebase,  white -to-yellow  solid. The IPI-549 drug product is formulated in 
2 different capsule strengths (5 mg and 30 mg) for oral delivery with excipients (diluent, disintegrant,  
and lubricant) that are listed in the FDA Inactive Ingredients Database for approved drug products  
and/or Generally  Regarded as Safe.  
 
Availability:  Provided by Infinity  Pharmaceuticals Inc.  
 
How supplied:  IPI-549 is administered as an oral capsule supplied at the dose specified per subject  
and/or cohort. 
 
Route  of administration for this  study:  IPI-549 should be self -administered orally (approximately 
every  24 hours). IPI-549 should be swallowed  whole with a glass  of water  (approximately 8 ounces or 
240 mL). Subjects must avoid grapefruit and grapefruit juice while on study drug. Subjects should be  
advised  to avoid  food and liquids  other  than water  from 2 hours prior to dosing until 1 hour after dosing. 
 
Side effects:  
 
Adverse Reactions  Based  on Clinical Data  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  29 of 45  
 The following side effects have been observed in 12 people who received IPI -549 according to the  
results from a Phase 1/1b first -in-human, dose escalation study to evaluate the safety tolerability,  
pharmacokinetics,  and pharmacodynamics of IPI-549 monotherapy and in combination  with 
nivolumab in subjects with advanced solid tumors. 
 
Grade 3 or higher  TEAEs  occurred in 5 (41.7%) subjects (1 each in the 10,15, and 20mg groups and 2 
in the 30mg group.)There was 1 occurrence of each of the following Grade 3 or higher TEAEs:  
anaemia, haematochezia, small intestinal obstruction, pneumonia, lymphocyte count decreased, and  
malignant neoplasm progression. 
 
Treatment -emergent SAEs occurred in 5 (41.7%) subjects. Each subject had 1 SAE as follows:  
malignant neoplasm progression (15mg), haematochezia (20mg), periotonitis (20mg), small intestinal  
obstruction (30mg), and pneumonia (30mg). 
 
The following side effects  have been  observed  in 56 people who received  IPI-549. 
 
Blood and lymphatic system  disorders:  
Anemia  
 
Gastrointestinal Disorders:  
Diarrhea  
Nausea  
Vomiting  
Abdominal pain 
 
General  disorders  and administration site conditions: 
Fatigue  
Fever  
Local  swelling  
 
Metabolism  and nutrition  Disorders:  
Hypomagnesaemia  
 
Nervous  system  disorders:  
Headache  
 
Vascular disorders  
Hypertension  
 
Skin  and subcutaneous  tissue  disorders:  
Rash  
Itchiness  
Dermatitis  acneiform  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  30 of 45  
 Investigations: 
Increased  liver enzymes  
White  blood cell count decreased  
Blood bilirubin increased 
 
Respiratory,  thoracic and mediastinal disorders:  
Shortness of breath  
Pleuritic  pain 
 
 
 
9.0 STATISTICAL  CONSIDERATIONS  
 
9.1 Study  populations  
The efficacy  population will consist of all  subjects who have received  2 weeks  of study drug.  
Any subject who has not received 2 weeks  of study drug will be  replaced.  
 
The safety  population will consist of all subjects who have received any  dose of study drug.  
 
 
9.2 Study  Design/Study  Endpoints  
We anticipate  enrolling 15 subjects . The primary  analysis  will use the efficacy  population. Within  
subject change from the post -treatment to the pre -treatment sample in the immune activation  
signature will be the primary  endpoint. We will test the hypothesis of an increase in this signature  
using a one sided paired t -test at 5% significance level.  With 15 subjects we have 80% power to  
detect  a difference  in the mean  signature  equal  to 0.68 standard  deviations, which  is a modest effect  
size. Although we lack preliminary data on the magnitude of the standard deviation of within  
subject changes, effect sizes less than this would be unlikely to be clinically interesting. Also, the  
differences seen between the poor prognosis and good prognosis groups in Kaneda et al. [2] were  
greater than this minimal effect  size. Thus the study appears to be well -powered to detect  
meaningful differences.  
 
 
 
 
Figure 1 : Illustration of shift in the  
signature distribution, which would yield 
an effect  size of  0.68  
  
 
9.3 Sample Size and Accrual  

UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  31 of 45  
 We anticipate enrolling 15 subjects . Subjects  who do not complete  2 weeks  of IPI-549 therapy  will 
be replaced.  Thus far, IPI-549 in advanced  cancer  patients  has been  well tolerated  without serious 
toxicity.  Therefore,  we anticipate  being  able to  fully  accrue this  trial within  one year of activation  
and the administration of IPI-549 will not interfere with planned surgery. If at any time 3 or more 
subjects  have observed  progression prior to the start of definitive  treatment  the study will be halted.  
 
Accrual  Targets  
Ethnic  Category  Sex/Gender  
Females  Males  Total  
Hispanic  or Latino  1 2 3 
Not Hispanic  or Latino  4 8 12 
Ethnic  Category:  Total  of all subjects  (A1)  (B1) (C1) 
Racial  Category  
American  Indian  or Alaskan  Native  0 0 0 
Asian  1 1 2 
Black  or African  American  1 1 2 
Native  Hawaiian  or other  Pacific  Islander  0 0 0 
White  3 8 11 
Racial  Category:  Total  of all subjects  (A2)  (B2) (C2) 
 (A1 = A2) (B1 = B2) (C1 = C2) 
 
9.4 Safety  stopping rule 
The study will be stopped early in the event of excessive toxicity leading to delays in definitive  
surgery. In particular any grade 3 toxicity will result in discontinuation of IPI -549, and any 
subject who has not received 2 weeks of study drug will be replaced. If at any time 3 or more  
subjects have observed progression prior to the star t of definitive treatment the study will be  
halted.  In addition, if at any time 3 or more subjects have surgery delayed by one week or more 
because of adverse events at least possibly related to study drug, the study will be halted.  These 
safety  stopping r ules will be  assessed  at least bi -annually  in a formal safety  report.  
 
9.5 Secondary  analyses  
Safety analysis: The safety analysis will use the safety population. Adverse events will be 
summarized  by grade,  attribution,  and system organ class.  
Secondary efficacy analyses: Subjects will have clinical tumor measurement prior to initiating  
IPI-549 and after 2 weeks administration of IPI -549. Only clinical measurement of disease will  
be performed. If clinical assessment is not feasible, this will be indicated on the CRF with the 
reason.  
   
 
10.0 STUDY  MANAGEMENT  
 
10.1 Conflict  of Interest  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  32 of 45  
 Any investigator who has  a conflict  of interest  with  this study  (patent  ownership, royalties,  or 
financial gain greater than the minimum allowable by their institution, etc.) must have the 
conflict  reviewed according  to UCSD conflict of interest policy.  
 
10.2 Institutional  Review  Board  (IRB)  Approval  and Consent  
In accordance with federal  regulations (21 CFR  312.66), an Institutional Review  Board  (IRB)  that 
complies with regulations in 21 CFR 56 must review and approve this protocol and the informed consent form  prior  to initiation  of the study.  The IRB should approve the consent  form  and protocol 
prior to any study- related  activities.  It is expected  that the IRB will have the proper representation  
and function in accordance with federally  mandated  regulations. 
 
In obtaining and documenting informed  consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to Good  Clinical Practice (GCP) and to  
ethical  principles that have their  origin in the Declaration  of Helsinki.  
 
Before recruitment and enrollment onto this study, the patient will be given a full explanation of  
the study and will be given the opportunity to review the consent form. Each consent form must  
include all the relevant elements currently required by the FDA Regulations and local or state  
regulations. Once this essential information has been provided to the patient and the investigator  
is assured  that the patient  understands the implications  of participating  in the study,  the patient  will 
be asked to  give consent to participate  in the study by signing an IRB-approved consent form.  
 
Prior to a patient’s participation in the trial, the written informed consent form should be signed  
and personally dated by the patient and by the person who conducted the informed consent  
discussion. The Principal Investigator or her associate must explain verbally and in writing the nature, duration, and purpose of the study and possible consequences of treatment. Patients must also be  
informed  that they may withdraw from  the study  at any time and for any reason  without 
jeopardizing their future treatment. In accordance with federal regulations (21 CFR 312), all  
patients must sign the IRB -approved consent form in the presence of a witness. Prior to the start  
of the study,  a copy  of the IRB -approved consent form  must be submitted  to the Sponsor. 
 
10.3 Subject  Data  Protection  
In accordance with the Health Information  Portability  and Accountability Act (HIPAA),  subjects  
who have provided written informed consent must also sign a subject authorization to release medical information to the study Sponsor and allow a regulatory authority, or Institutional Review  Board access  to subject ’s medical  information relevant to  the study.  
 
10.4 Data  and Safety  Monitoring/Auditing  
In addition to adverse event  monitoring and clinical oversight by the  Study Chair  and co- 
investigators, quality assurance of the study will be performed  by the UCSD Moores Cancer  Center  
Clinical Trials Office internal monitor. Monitoring intervals will be dependent upon the number  
of patients enrolled and the complexity  of the study. 
 
This study will also use the UCSD Moores Cancer  Center  Data  Safety  and Monitoring Board  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  33 of 45  
 (DSMB)  to provide oversight in  the event  that this treatment  approach  leads  to unforeseen  
toxicities.  Data from this study  will be reported and will include: 
 
1) the protocol title,  IRB protocol number, and  the activation  date of the study.  
2) the number of patients enrolled  to date 
3) the dates  of patient  enrollment 
4) a summary  of all adverse events regardless  of grade  and attribution  
5) a response evaluation  for evaluable patients  when available  
6) a summary  of any  recent  literature  that may  affect  the ethics of  the study.  
 
10.5 Adherence to the Protocol  
Except  for an emergency  situation  in which  proper care for the protection, safety,  and well -being  
of the study patient requires alternative treatment, investigators are required to conduct their  
research  according  to the plans reviewed  and approved by the IRB.  
 
10.6 Amendments to the Protocol  
Should amendments to the protocol be required, the amendments will be originated and 
documented by  the Study Chair.  It should also be noted that  when  an amendment  to the protocol 
substantially alters the study design or the potential risk to the patient, a revised consent form might be required. 
 
The written  amendment,  and if required  the amended consent  form,  must be sent to the IRB  for 
approval prior to implementation.  
 
10.7 Record Retention  
Study documentation includes all Case Report Forms, data correction forms or queries, source  
documents, Sponsor- Investigator  correspondence,  monitoring  logs/letters,  and regulatory 
documents (e.g., protocol and amendments, IRB correspondence and approval, signed patient  
consent forms).  
 
Source documents include all recordings of observations or notations of clinical activities and all  
reports  and records  necessary  for the evaluation and  reconstruction of the clinical  research  study.  
 
Government agency regulations and directives require that the study investigator must retain all study documentation pertaining to the conduct of a clinical  trial.  In the case of a study with a drug 
seeking  regulatory  approval and marketing,  these documents shall  be retained  for at least two years  
after the last approval of marketing application in an International Conference on Harmonization  
(ICH) region. In all other cases, study documents should be kept on file until three years after the  
complet ion and final study report of this investigational study.  
Obligations  of Investigators 
The Principal  Investigator  is responsible for the conduct of the clinical  trial at the site in accordance  
with Title  21 of the Code of Federal  Regulations and/or the Declaration  of Helsinki.  The Principal  
Investigator is responsible for personally overseeing the treatment of all study patients. The  
Principal Investigator must assure that all study site personnel, including sub- investigators and  
other study staff member s, adhere to the study protocol and all FDA/GCP/NCI  regulations and 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  34 of 45  
 guidelines regarding  clinical  trials  both during and after  study completion. 
 
The Principal Investigator at each institution or site will be responsible for assuring that all the 
required data will be collected and entered onto the Case Report Forms. Periodically, monitoring  
visits will be conducted and the Principal Investigator will provide access to his/her original  
records  to permit  verification  of proper entry  of data.  At the completion  of the study,  all case report  
forms will be reviewed by the Principal Investigator and will require his/her final signature to  
verify  the accuracy  of the data.  
 
11.0 Ethical  considerations  
 
11.1 Ethical  Conduct  of Study 
This study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practices  (GCP) guidelines.  The Principal Investigator  or qualified  designees  are responsible for 
reporting to the authorities and IRB amendments, safety updates and protocol violations that impact  subject safety.  
 
11.2 Subject  Data  Protection  
In accordance with the Health Information Portability and Accountability Act (HIPAA),  
subjects who have provided written informed consent must also sign a subject authorization to  
release medical  information  to the study Sponsor and allow  a regulatory authority, or Institutional  
Review  Board access  to subject’s medical  information relevant to  the study.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  35 of 45  
  
 
 
  
 
12.0 REFERENCES  
 
1. Kaneda, M.M., et al., Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma 
Progression. Cancer  Discovery, 2016. 6(8): p. 870. 
2. Kaneda,  M.M., et al., PI3Kγ  is a molecular switch  that controls immune  suppression. 
Nature,  2016. 539(7629): p. 437-442. 
3. De Palma,  M. and Claire E.  Lewis,  Macrophage Regulation of Tumor Responses to 
Anticancer  Therapies. Cancer  Cell, 2013. 23(3):  p. 277-286. 
4. Gabrilovich, D.I., S. Ostrand -Rosenberg, and V. Bronte, Coordinated regulation of 
myeloid  cells by tumours. Nat Rev  Immunol, 2012. 12(4): p. 253-268. 
5. Schmid, M.C., et al., Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate  
myeloid  cell PI3Kγ,  a single convergent point promoting tumor inflammation  and 
progression. Cancer  cell, 2011. 19(6): p. 715-727. 
6. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: Revised  
RECIST  guideline (version  1.1). European Journal of Cancer,  2009. 45(2):  p. 228-247. 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  36 of 45  
  
 
 
     
 
  
 
13.0 APPENDICES  
 
Appendix A. Performance Status  
 
ECOG  Performance  Status  Scale  Karnofsky  Performance  Scale  
Grade  Descriptions  Percent  Description  
0 Normal  activity.  Fully  
active, able to carry on all  
pre-disease performance 
without restriction.  100 Normal,  no complaints,  no 
evidence  of disease  
90 Able  to carry  on normal  
activity; minor signs  or 
symptoms  of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically  
strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office  work).  80 Normal activity with effort;  
some signs or symptoms of  
disease.  
70 Cares for self, unable to carry  
on 
normal activity or to do active  
work  
2 In bed < 50% of the time.  
Ambulatory and capable of  
all self -care, but unable to 
carry  out any work  activities.  
Up and about more  than 50% 
of waking  hours.  60 Requires  occasional  
assistance,  but is able to care  
for most of  his/her  needs.  
50 Requires considerable  
assistance and frequent 
medical  care 
3 In bed > 50% of the time.  
Capable of only limited self - 
care, confined to bed or chair more  than 50% of waking  
hours  40 Disabled,  requires  special  care 
and assistance.  
30 Severely  disabled,  
hospitalization  indicated.  
Death  not imminent  
4 100% bedridden.  
Completely disabled. Cannot carry  on any self- 
care.  Totally confined to bed 
or chair  20 Very  sick, hospitalization  
indicated.  Death  not imminent.  
10 Moribund,  fatal processes  
progressing rapidly 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  37 of 45  
  
5 Dead.  0 Dead.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  38 of 45  
 Appendix B: Patient  Pill Diary  [be sure  to bring  this diary  and pill bottles  with you to your  
next study  visit.  
 
Study #:  
Patient  ID: 
Patient  name:  
Patient  Signature:  Date:  
Day Number  Day of the week  Date  IPI-549 (mg)  Comments  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
     
     
     
     
     
     
     
     
     
     
     
     
     
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  39 of 45  
 Appendix C: Medications or foods known to inhibit or  induce  CYP3A  
 
The following list provides medications known to induce or inhibit CYP3A activity. Note that 
this 
is not a comprehensive list of all medications  which  may  modulate CYP3A activity.  Additional 
information  can be found at: 
 
• http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/  
ucm292362.pdf 
 
Note:  Subjects  receiving  IPI-549 are prohibited from  concomitant use of medications  or foods 
that are known to be strong inhibitors or inducers of CYP3A.  
 
Classification  of In Vivo Inhibitors of CYP3A  
 
Strong  Inhibitors(1) Moderate  inhibitors(2) Weak  inhibitors(3) 
Boceprevir,  
clarithromycin,  conivaptan,  
grapefruit juice,(5) indinavir,  
itraconazole, ketoconazole,  
lopinavir/ritonavir,  
mibefradil,(6) 
nefazodone, nelfinavir,  
posaconazole, ritonavir,  
saquinavir,  
telaprevir,  
telithromycin,  
voriconazole Amprenavir, aprepitant,  
atazanavir, ciprofloxacin,  
darunavir/ritonavir, diltiazem,  
erythromycin, fluconazole,  
fosamprenavir,  grapefruit  juice,  Alprazolam, amiodarone,  
amlodipine, atorvastatin,  
bicalutamide,  cilostazol,  cimetidine,  
cyclosporine, fluoxetine,  
fluvoxamine, ginkgo, (4) 
goldenseal,(4) 
isoniazid,  nilotinib,  
oral contraceptives,  ranitidine,  
ranolazine,  
tipranavir/ritonavir,  zileuton  
1.   A strong inhibitor for a specific CYP is defined as an inhibitor that increases the area under  the 
curve (AUC) of a substrate for that CYP by equal or more than 5 -fold or > 80% decrease in 
clearance (CL).  
2. A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a  
sensitive substrate for that CYP by less than 5 -fold but equal to or more than 2- fold or 50% - 
80% decrease in CL. 
3. A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive 
substrate for that CYP by less than 2- fold but equal to or more than 5 -fold or 20% - 50% 
decrease in CL. 
4. Herbal  product.  
5. The effect of grapefruit juice varies widely among brands and is concentration- , dose- , and  
preparation- dependent. Studies have shown that it can be classified as a “strong CYP3A  
inhibitor” when a certain preparation was used (eg, high- dose, double -strength) or as a 
“moderate CYP3A inhibitor” when another preparation was  used (eg,  low-dose,  single - 
strength).  
6. Withd rawn  from the United States  market  because of safety  reasons.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  40 of 45  
  
 
 
 
Protocol  IPI-549-01 Infinity Pharmaceuticals, Inc.  
IPI-549 
 
Classification  of In Vivo Inducers  of CYP3A 
 
Strong  Inducers  ≥ 80% 
decrease in AUC Moderate Inducers 50 -80% 
decrease  in AUC Weak Inducers 20 -50% 
decrease  in AUC 
Avasimibe,(1) 
carbamazepine,  phenytoin,  
rifampin,  St. John’s  Wort(2) Bosentan, efavirenz,  
etravirine,  modafinil,  nafcillin  Amprenavir, aprepitant,  
armodfinanil, Echinacea,(3) 
pioglitazone, prednisone,  
rufinamide  
1. Not a  marked drug.  
2. The effect  of St. John’s  Wort  varies  widely  and is preparation -dependent.  
3. Herbal  product.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  41 of 45  
  
 
 
 
 
Appendix D: Medications associated with prolongation of the QTC  and/or  with torsades  de 
pointes  
 
Medications that prolong the QT interval and/or have a risk of inducing Torsades de Pointes are  
listed below. Below, these drugs are divided into two groups based on their known or perceived  
risk of causing  Torsades  de Pointes. These lists show  examples  only, and  are not comprehensive. 
 
Medications from Group 1 are prohibited throughout the trial. Medications from Group 2 may be  
allowed  in selected  circumstances after  consultation with the medical monitor.  
 
Additional information  can be found at: http://www.azcert.org/medical-pros/drug-  
lists/bycategor.cfm  
 
Group 1 Drugs:  Generally  Accepted  to Have a  Risk  of Causing  Torsades de Pointes  
 
Amiodarone  
Arsenic trioxide 
Bepridil  
Chlorpromazine  
Chloroquine Cisapride  
Disopyramide Dofetilide  
Domperidone 
Droperidol  
Erythromycin  
Halofantrine 
Haloperidol  Ibutilide  
Levomethadyl  
Mesoridazine Methadone 
Moxifloxacin  
Pentamidine Pimoz ide 
Probucol  
Procainamide Quinidine 
Sotalol  
Sparfloxacin Thioridazine Vandetanib 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  42 of 45  
  
 
 
 
 
Group 2 Drugs : Drugs That in Some Reports May be Associated with QTc Prolongationand/or 
Torsades  de Pointes, but Lack Substantial Evidence of Causing Torsades dePointes 
 
Alfuzosin  
Amantadine 
Atazanavir  
Azithromycin  
Chloral hydrate Clozapine  
Dolasetron Dronedarone 
Escitalopram  
Felbamate 
Flecainide 
Foscarnet  
Fosphenytoin Gatifloxacin 
Gemifloxacin Granisetron 
Indapamide 
Isradipine 
Lapatinib 
Levofloxacin 
Lithium  
Moexipril/HCTZ  Nicardipine  
Nilotinib  
Octreotide Ofloxacin  
Ondansetron 
Oxycodone 
Paliperidone 
Quetiapine 
Ranolazine 
Risperidone Roxithromycin  
Sertindole Sunitinib  
Tacrolimus  
Tamoxifen Telithromycin  
Tizanidine Vardenafil  
Venlafaxine Voriconazole 
Ziprasidone 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  43 of 45  
  
 
 
  
 
Appendix E: CYP2C8  OR CY2C9  SUBSTRATES  
 
The following lists  provide known sensitive  CYP2C8  or CYP2C9  substrates.  
 
Medications that are metabolized via CYP2C8 or CYP2C9 should be used with caution. Those 
with a narrow  therapeutic  range  are prohibited during the trial. 
 
Additional information can be found at  
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm2 
92362.pdf.  
 
CYP2C8  Substrates  
paclitaxel  cerivastatin  
torsemide  rosiglitazone  
amodiaquine  repaglinide  
 pioglitazone  
CYP2C9  Substrates  
celecoxib  Warfarin*  
Phenytoin*  glipizide  
*Substrates  with a narrow  therapeutic  range  are prohibited throughout  the trial 
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  44 of 45  
  
 
 
    
 
Appendix F: P-GP Substrates  and medications that are inhibitors  of P-GP 
 
The following list provides medications that are substrates or inhibitors of P -gp. Substrates of P - 
gp should be used with caution during treatment with IPI- 549. Inhibitors of P -gp are prohibited 
during treatment with IPI -549. Note that this is not a comprehensive list of all medications which 
may be substrates  of P-gp or  may modulate  P-gp activity.  
 
P-gp Substrates  
Amitriptyline  Loperamide  
Amiodarone  Losartan  
Atorvastatin  Lovastatin  
Cefoperazone  Methadone  
Chlorpromazine  Methotrexate  
Cimetidine  Methylprednisolone  
Ciprofloxacin  Morphine  
Clarithromycin  Nadolol  
Colchicine  Norfloxacin  
Cyclosporine  Nortriptyline  
Dexamethasone  Ondansetron  
Digoxin  Omeprazole  
Diltiazem  Pantoprazole  
Erythromycin  Phenytoin  
Estradiol  Pravastatin  
Fentanyl  Propranolol  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  45 of 45  
  
Fexofenadine  Quinidine  
Hydrocortisone  Ranitidine  
Intraconazole  Sirolimus  
Lansoprazole  Tacrolimus  
Levofloxacin  Timolol  
Lidocaine  Trimethroprim  
 Verapamil  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  46 of 45  
  
 
 
   
 
P-gp Inhibitors  
Amiodarone  Lovastatin  
Amitriptyline  Mefloquine  
Carvedilol  Nicardipine  
Chlorpromazine  Nifedipine  
Clarithromycin  Ofloxacine  
Cortisol  Omeprazole  
Cyclosporine  Pantoprazole  
Desipramine  Progesterone  
Diltiazem  Propafenone  
Dipyridamole  Propranolol  
Doxepin  Quinidine  
Erythromycin  Rifampicin  (Rifampin)  
Felodipine  Saquinavir  
Fluphenazine  Simvastatin  
Grapfruite  juice Sirolimus  
Haloperidol  Tacrolimus  
Itraconazole  Testosterone  
Ketoconazole  Verapamil  
Source: Atkinson AJ et al. Principles of Clinical Pharmacology, 2nd ed. Academic Press,  
Massachusetts,  2007.  
UCSD  Moores  Cancer  Center  
Phase  2 Window  Study  of IPI-549 in Locally  Advanced  HNSCC  CONFIDENTIAL  
UCSD  IIT Cohen  172058  
Protocol Version: 5.0 
Protocol  Date: January  15, 2021  Page  47 of 45  
 Appendix G: Pharmacodynamic changes observed in peripheral blood of MARIO3 TNBC  
patients after 15 day treatment with eganelisib in combination with atezolizumab + nab - 
paclitaxel  
 
Source:  Infinity  
